Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: AbbVie | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: AbbVie

18% growth driven by HUMIRA, up 12% to $3.6 billion in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie
 
3Q Revenues: $5.9 billion (+18)

3Q Earnings: $1.2 billion  (earnings were $506 million 3Q14)

YTD Revenues: $16.5 billion (+13%)

YTD Earnings: $3.6 billion (+41%)

Comments: Growth was driven by the continued strength of HUMIRA, up 12% to $3.6 billion in the quarter. IMBRUVICA sales were $304 million and VIEKIRA sales were $469 million in the quarter. Duodopa, Creon and Lupron sales were up 9%, 8%, and 2% respectively, while Kaletra sales declined 34% to $168 million, AndroGel sales were down 24% to $177 million, and Synagis sales were down 15% to $93 million. R&D expenses were $1.4 billion in the quarter, up from 812 million in 3Q14.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters